---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000068"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:48:23.754825+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Entrada doses first participant in Phase 1 trial of ENTR-601-44 for Duchenne MD

## Summary
- First participant dosed in Phase 1 trial of ENTR-601-44 for DMD patients amenable to exon 44 skipping.
- Trial conducted in UK; targets ~40 healthy male volunteers; endpoints include safety, PK, and target engagement.
- Data from the Phase 1 trial expected in the second half of 2024.
- Initiation marks Entrada's transition into a clinical-stage company.

## SEC filing metadata
- accession: 0001689375-23-000068
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/0001689375-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000068/trda-20230921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000068
- JSON: https://secwatch.observer/filing/0001689375-23-000068.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.